» Articles » PMID: 30326299

Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis

Overview
Specialty Gastroenterology
Date 2018 Oct 17
PMID 30326299
Citations 125
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Bariatric surgery has been reported to lead to complete resolution of nonalcoholic fatty liver disease (NAFLD) following the sustained weight loss induced in obese patients. We performed a systematic review and meta-analysis to evaluate the effects of bariatric surgery on NAFLD in obese patients.

Methods: We searched MEDLINE, EMBASE, CENTRAL, and Web of Science databases through May 2018 for studies that compared liver biopsy results before and after bariatric surgery in obese patients. Primary outcomes were biopsy-confirmed resolution of NAFLD and NAFLD activity score. Secondary outcomes were worsening of NAFLD after surgery and liver volume. The Grading of Recommendations, Assessment, Development, and Evidence approach was conducted to assess overall quality of evidence.

Results: We analyzed data from 32 cohort studies comprising 3093 biopsy specimens. Bariatric surgery resulted in a biopsy-confirmed resolution of steatosis in 66% of patients (95% CI, 56%-75%), inflammation in 50% (95% CI, 35%-64%), ballooning degeneration in 76% (95% CI, 64%-86%), and fibrosis in 40% (95% CI, 29%-51%). Patients' mean NAFLD activity score was reduced significantly after bariatric surgery (mean difference, 2.39; 95% CI, 1.58-3.20; P < .001). However, bariatric surgery resulted in new or worsening features of NAFLD, such as fibrosis, in 12% of patients (95% CI, 5%-20%). The overall Grading of Recommendations, Assessment, Development, and Evidence quality of evidence was very low.

Conclusions: Through this systematic review and meta-analysis, we found that bariatric surgery leads to complete resolution of NAFLD in obese patients. However, some patients develop new or worsened features of NAFLD. Randomized controlled trials are needed to further examine the therapeutic benefits of bariatric surgery for patients with NAFLD.

Citing Articles

The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease.

Eslam M, Fan J, Yu M, Wong V, Cua I, Liu C Hepatol Int. 2025; .

PMID: 40016576 DOI: 10.1007/s12072-024-10774-3.


Therapeutic Targets and Approaches to Manage Inflammation of NAFLD.

Geng W, Liao W, Cao X, Yang Y Biomedicines. 2025; 13(2).

PMID: 40002806 PMC: 11853636. DOI: 10.3390/biomedicines13020393.


Duodenal Organoids From Metabolic Dysfunction-Associated Steatohepatitis Patients Exhibit Absorptive and Barrier Alterations.

Hadefi A, Leprovots M, Dinsart G, Marefati M, Vermeersch M, Monteyne D Gastro Hep Adv. 2025; 4(4):100599.

PMID: 39996241 PMC: 11849614. DOI: 10.1016/j.gastha.2024.100599.


Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.

Bril F, Berg G, Barchuk M, Nogueira J J Lipid Atheroscler. 2025; 14(1):5-29.

PMID: 39911965 PMC: 11791423. DOI: 10.12997/jla.2025.14.1.5.


Preventing the progression of cirrhosis to decompensation and death.

Villanueva C, Tripathi D, Bosch J Nat Rev Gastroenterol Hepatol. 2025; .

PMID: 39870944 DOI: 10.1038/s41575-024-01031-x.